Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is expected to see strong growth in the coming years due to the commercialization of its flagship product, DefenCath, and the diversification of its portfolio through the acquisition of Momenta. The company has already achieved significant operating synergies and has a strong cash position with near-zero net debt. The potential launch of Rezzayo and DefenCath in the Total Parenteral Nutrition market could provide additional revenue streams and significantly increase the company's market potential. Despite the recent stock reaction, the company's potential for sustained growth and successful clinical execution make it a promising investment opportunity.

Bears say

Cormedix is a biopharmaceutical company with a negative outlook as the launch of its new drug Rezzayo for prophylaxis in high-risk immunocompromised patients is not expected until 2026 and there are uncertainties around its peak penetration. Additionally, the company may require additional funding to achieve sustainable profitability and there is no guarantee of obtaining favorable financing terms or attracting new partners. The existing treatment franchise is conservatively valued due to formulary dynamics, shorter treatment duration and measured hospital adoption, further limiting potential revenue growth.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.